vicadrostat

Vicadrostat is an orally bioavailable, potent, and highly selective small molecule inhibitor of aldosterone synthase. It is being developed primarily for the treatment of chronic kidney disease (CKD) and heart failure. By inhibiting aldosterone synthase, vicadrostat reduces the production of aldosterone—a hormone involved in regulating blood pressure and fluid balance—thereby aiming to slow CKD progression and reduce cardiovascular risk. Clinical trials have shown dose-dependent reductions in albuminuria and blood pressure in patients with CKD, both as monotherapy and when combined with empagliflozin. The drug is under development by Boehringer Ingelheim[1][2][4][5][6].

Other names

vicadrostat [INN]2-chloro-4-((6R)-6-(hydroxymethyl)-6-methyl-4-oxo-6,7-dihydropyrano(3,4-d)imidazol-3(4H)-yl)benzonitrile